285 related articles for article (PubMed ID: 25372757)
1. Transthyretin microheterogeneity and molecular interactions: implications for amyloid formation.
Landreh M; Ostberg LJ; Pettersson TM; Jörnvall H
Biomol Concepts; 2014 Jun; 5(3):257-64. PubMed ID: 25372757
[TBL] [Abstract][Full Text] [Related]
2. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Lashuel HA; Lai Z; Kelly JW
Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
[TBL] [Abstract][Full Text] [Related]
4. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation.
Ferreira N; Saraiva MJ; Almeida MR
FEBS Lett; 2011 Aug; 585(15):2424-30. PubMed ID: 21740906
[TBL] [Abstract][Full Text] [Related]
5. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D
J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037
[TBL] [Abstract][Full Text] [Related]
6. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
7. Cooperative stabilization of transthyretin by clusterin and diflunisal.
Greene MJ; Klimtchuk ES; Seldin DC; Berk JL; Connors LH
Biochemistry; 2015 Jan; 54(2):268-78. PubMed ID: 25478940
[TBL] [Abstract][Full Text] [Related]
8. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis.
Foss TR; Kelker MS; Wiseman RL; Wilson IA; Kelly JW
J Mol Biol; 2005 Apr; 347(4):841-54. PubMed ID: 15769474
[TBL] [Abstract][Full Text] [Related]
9. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW
Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320
[TBL] [Abstract][Full Text] [Related]
10. The sequence-dependent unfolding pathway plays a critical role in the amyloidogenicity of transthyretin.
Yang M; Yordanov B; Levy Y; Brüschweiler R; Huo S
Biochemistry; 2006 Oct; 45(39):11992-2002. PubMed ID: 17002298
[TBL] [Abstract][Full Text] [Related]
11. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
[TBL] [Abstract][Full Text] [Related]
12. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
Lashuel HA; Wurth C; Woo L; Kelly JW
Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
[TBL] [Abstract][Full Text] [Related]
13. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.
Almeida MR; Macedo B; Cardoso I; Alves I; Valencia G; Arsequell G; Planas A; Saraiva MJ
Biochem J; 2004 Jul; 381(Pt 2):351-6. PubMed ID: 15080795
[TBL] [Abstract][Full Text] [Related]
14. A New Folding Kinetic Mechanism for Human Transthyretin and the Influence of the Amyloidogenic V30M Mutation.
Jesus CS; Almeida ZL; Vaz DC; Faria TQ; Brito RM
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589730
[TBL] [Abstract][Full Text] [Related]
15. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
[TBL] [Abstract][Full Text] [Related]
16. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
Lai Z; Colón W; Kelly JW
Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
[TBL] [Abstract][Full Text] [Related]
17. The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin.
Morais-de-Sá E; Neto-Silva RM; Pereira PJ; Saraiva MJ; Damas AM
Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):512-9. PubMed ID: 16627944
[TBL] [Abstract][Full Text] [Related]
18. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization.
Hurshman AR; White JT; Powers ET; Kelly JW
Biochemistry; 2004 Jun; 43(23):7365-81. PubMed ID: 15182180
[TBL] [Abstract][Full Text] [Related]
19. Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 mitigates amyloidogenesis.
Sörgjerd K; Ghafouri B; Jonsson BH; Kelly JW; Blond SY; Hammarström P
J Mol Biol; 2006 Feb; 356(2):469-82. PubMed ID: 16376939
[TBL] [Abstract][Full Text] [Related]
20. Thyroxine interactions with transthyretin: a comparison of 10 different naturally occurring human transthyretin variants.
Rosen HN; Moses AC; Murrell JR; Liepnieks JJ; Benson MD
J Clin Endocrinol Metab; 1993 Aug; 77(2):370-4. PubMed ID: 8345041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]